A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies

Trial Profile

A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Sapanisertib (Primary) ; TAK 580 (Primary) ; Alisertib; Cetuximab; Irinotecan; Paclitaxel
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Jul 2018 to 23 Dec 2017.
    • 18 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 23 Dec 2017.
    • 14 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top